Background: Although depression and anxiety have been associated with shorter telomeres in cross-sectional studies, the data regarding the prospective relations of depression and anxiety to accelerated telomere length shortening are limited and findings are mixed. We prospectively examined relations of baseline depression and phobic anxiety to subsequent 11-year change in relative leukocyte telomere lengths (LTLs).
naturally shorten over time with mitosis, and cells may undergo senescence or apoptosis after telomeres reach critically short lengths (Bojesen, 2013) . However, under conditions of heightened oxidative, inflammatory, or other cellular stress, telomere shortening may be accelerated. Therefore, telomere shortening may serve as an indicator of biological or cellular aging, reflecting damage accumulated over time.
Telomere length has been associated with mortality and age-related morbidity, including cancer and cardiovascular disease (Fitzpatrick et al., 2007; Willeit et al., 2010; Zhu, Belcher, & Harst, 2011) , and could potentially mediate the pathophysiology between depression or anxiety and subsequent somatic conditions (Gotlib et al., 2015) .
Nevertheless, the nature and direction of the relationships of depression and anxiety to leukocyte telomere length are not entirely clear. It seems possible that depression and anxiety may precede telomere attrition (Hoen et al., 2013; Shalev et al., 2014) or vice versa (Ramin et al., 2015; Wium-Andersen, Orsted, Rode, Bojesen, & Nordestgaard, 2017) ; it is also plausible that depression and telomere shortening share common causes such as lifestyle factors or genetic predisposition. Several cross-sectional studies and a few prospective studies have examined these associations with inconsistent findings (Darrow et al., 2016; Lin, Huang, & Hung 2016; Schutte & Malouff, 2015) . These inconsistencies may be explained by differences in study design (cross-sectional vs. longitudinal) (Schutte & Malouff, 2015) , sample composition (clinical sample vs. general population), age range (younger, mid-life, or older), measurement of psychiatric variables (self-report vs. diagnostic interview, symptoms vs. diagnoses), psychiatric illness status (past/remitted vs. current case), type of telomere length assay (Southern blot, fluorescence in situ hybridization, or quantitative PCR [qPCR] ) (Lin, Huang, & Hung, 2016) , and the level of detail in adjustment for confounders. Most positive associations come from cross-sectional studies, nearly half of which featured small sample sizes (N < 100).
Prospective studies of associations between depression and/or anxiety and subsequent telomere length shortening featured variable follow-up periods, ranging from 2 to 12 years, and findings have been inconsistent (Hoen et al., 2011 (Hoen et al., , 2013 Rius-Ottenheim et al., 2012; Shalev et al., 2014; Verhoeven, van Oppen, Revesz, Wolkowitz, & Penninx, 2016) . Specifically, significant associations were seen among young male adults and older men with heart disease in which significance disappeared after further adjustment for covariates. Potential sources of the discrepant findings across prospective studies include variations in sample size, age, sex, health characteristics (healthy population/patients with heart disease), and follow-up durations. In addition, several studies examined the impact of changes of depressive symptoms on changes of telomere lengths across two time points (Rius-Ottenheim et al., 2012; Shalev et al., 2014; Verhoeven et al., 2016) ; however, changes in depression and telomere length were assessed concurrently (i.e., overlapping) rather than sequentially.
Because these designs did not feature a baseline period of change in depression, followed by a subsequent period of change in telomeres, the nature of the temporal association was unclear. In addition, it is not known whether depression and anxiety have similar relations to telomere shortening. For example, Verhoeven et al. (2016) found people with depression and people with anxiety both had consistently shorter telomere lengths at follow-up, whereas Hoen et al. (2013) identified decreasing leukocyte telomere lengths (LTLs) only among people with the presence of anxiety but not depression. Overall, it remains unclear whether depression and anxiety leads to accelerated shortening of telomere length over time.
To address the above limitations and gaps in the knowledge base, we aimed to investigate the prospective relationship between baseline depression and phobic anxiety, typically a chronic form of anxiety, and subsequent 11-year changes in telomere length in a well-characterized sample of mid-life and older U.S. women (N = 1,250), which particularly addressed potential age-and gender-specific associations in the literature. We hypothesized that women with depression or phobic anxiety at baseline would have acceleration in telomere attrition after 11 years compared to those without these conditions.
METHODS AND MATERIALS

Study population
The Nurses' Health Study (NHS) is a prospective cohort that began in 1976 when 121,700 female nurses living in 11 U.S. states, aged 30-55 years, returned a mailed questionnaire regarding lifestyle and medical history. Participants have received questionnaires biennially since then, with >90% follow-up in each 2-year cycle. Between 1989 and 1990 (T1), blood samples, along with information from a supplementary questionnaire, were collected from 32,826 NHS participants. Details of the blood collection have been described previously (Hankinson et al., 1995) . Among this blood subcohort, a subset of 18,717 women also provided a second blood sample in 2000-2001 (T2) . For the current study, we generated a random sample of 1,700 adults who provided blood samples at both T1 and T2, had information on phobic anxiety on the 1988 questionnaire and depressive symptoms on the 1992 questionnaire, were free of major chronic diseases including cancer and cardiovascular disease, and had not been selected as cases or controls in prior NHS telomere studies. Following exclusions described in detail below, the final sample for analysis included 1,250 women.
Assessment of depression and phobic anxiety
Antidepressant use was ascertained from the supplementary questionnaire that accompanied the first blood collection in 1989-1990. Information on depressive symptoms were first assessed with the 1992 cohort questionnaire using the Mental Health Inventory-5 (MHI-5) subscale of the 36-item Short-Form Health Status Survey (Ware & Sherbourne, 1992) ; the MHI-5 has been validated for detecting clinical depression and severe depressive symptoms (Berwick et al., 1991; Ware & Sherbourne, 1992) . Baseline depression was defined by selfreported antidepressant use or the presence of severe depressive symptoms (MHI-5 ≤ 52) (Yamazaki, Fukuhara, & Green, 2005) . In a secondary analysis, depression was alternatively defined by the presence of both antidepressant use and severe symptoms, such a Boolean AND definition tends to maximize case specificity, and potentially reduce bias in estimates, but to have substantially lower case detection.
Phobic anxiety was assessed using the phobic subscale of the Crown-Crisp Experiential Index (CCI) (Crown & Crisp, 1966) on the 1988 cohort questionnaire. The CCI contained eight items assessing fear and desire for avoidance; each item has 2-3 levels of possible response (between 0 and 2 points), leading a sum score for all items ranging from 0 to 16 points. Higher scores indicate greater levels of phobic anxiety. The CCI has been validated in psychiatric outpatient clinics and has been shown to have good discrimination (Burgess, Mazzocco, & Campbell, 1987; Crown & Crisp, 1966) . CCI scores are not normally distributed (highly right-skewed), and in keeping with other work (Haines, Cooper, & Meade, 2001; McGrath et al., 2004; Okereke et al., 2012) , CCI scores were categorized into five categories according to total score: 0-1 (reference group), 2, 3, 4-5, and 6+ points.
Assessment of covariates
Information on covariates was obtained by either the supplementary questionnaire that accompanied the T1 blood collection or the most proximal biennial NHS questionnaire (i.e., 1988-1990 questionnaire cycle). Potential confounders were selected a priori based on prior literature (involving NHS or other cohorts), in which they were significantly associated with telomere lengths: age (years), paternal age at participant's birth (years) (Kimura et al., 2008; 
Assessment of relative LTL
LTLs in genomic DNA were measured using a modified, highthroughput version of the real-time qPCR-based telomere assay (Crown & Crisp, 1966; Wang et al., 2008) that was run on the Applied Biosystems 7900HT Sequence Detection System (Foster City, CA).
Specimens collected at T1 and T2 for each participant were placed side-by-side on the same plate to minimize influences of random measurement error on the paired samples. Experienced laboratory personnel were blinded to participants' characteristics, and all assays were processed in triplicate by the same technician and under identical conditions.
The amplification of genomic DNA from peripheral blood leukocytes was done for both telomere repeat copy number (T) and a single control gene (36B4) copy number (S). The average relative telomere length was calculated, and the ratio of telomere repeat copy number to a single gene copy number (T/S ratio) was proportional to the average telomere length (Cawthon, 2002) . Relative LTLs were reported as the exponentiated relative T/S ratio corrected for a reference sample (Nan et al., 2011) ; this measure correlates highly (r = 0.68-0.85; P < .001) with Southern blot measurement of absolute telomere lengths (Aviv et al., 2011; Cawthon, 2002) . The coefficient of variations (CVs) for the telomere and the single-gene assays in this study ranged from 0.10-1.98% and 0.04-1.57%, respectively. The CVs for the relative telomere lengths of quality control samples were 11.3-19.2%.
The mean duration between T1 and T2 among the study participants was 11.1 years (SD 0.5 years; range: 9.6-12.5 years). We calculated 11-year changes in LTLs using three metrics. First, we computed absolute change (AC), defined as absolute difference of LTLs between T2 and T1: LTL (T2) -LTL (T1) . Second, we computed symmetrized percent change (SPC) (Berry & Ayers, 2002) , defined as
; the advantage of SPC is that it is less sensitive to outliers and also takes into account baseline telomere length. Lastly, we calculated the decile shift (DS) (Benetos et al., 2013) , defined as the difference of decile ranking in LTLs between T2 and T1. We created the following DS categories: "stable" was defined as either maintenance of identical decile rank or a DS within ±1 decile; "shifting upward" and "shifting downward" were defined as >1 decile increase and >1 decile decrease, respectively, comparing T2 and T1 (Benetos et al., 2013) . Because rankings are used, instead of actual LTL values, DS is also less sensitive to outliers. The main goal was to examine the robustness and consistency of the association between depression and anxiety and changes in telomere length between three different metrics of change measures. Among 1,700 participants, we excluded 17 with samples at T1 with inadequate specimen volume, 22 with samples that failed the telomere assay runs at both time points, and an additional 229 with samples at T1 and 211 with samples at T2 that had within-triplicate CVs for the T/S ratio > 20%; thus, 1,432 and 1,467 participants remained with available LTLs at T1 and T2, respectively. A total of 1,250 women with LTLs available at both time points were included in the final analysis.
Statistical analysis
For the outcomes of AC and SPC, we used linear regression models to investigate the relations of baseline depression and phobic anxiety to 11-year changes in LTLs. Adjusted least squares mean 11-year changes in LTLs (and their corresponding 95% confidence intervals; 95% CIs) were calculated across depression and phobic anxiety categories using generalized linear models. For the DS outcome, multinomial logistic regressions were used. Model 1 adjusted for age and LTLs at baseline (i.e., T1). Model 2 additionally adjusted for potential confounders described above in Section 2.3. Statistical analyses were conducted using SAS v. 9.4 (SAS Institute Inc., Cary, NC). All P-values were two-sided, and a nominal level of 0.05 was used for statistical significance.
RESULTS
The age range of the participants was 48-69 years at baseline, with a mean of 56.9 years (SD 5.5 years). There was a modest but consistent inverse correlation between LTLs and age at both T1 and T2 (Figure 1 ): a one-year increase in age was correlated with a decrease in LTLs by 0.003 at both T1 and T2. The Pearson correlation coefficient was 0.72 (P < .0001) between LTLs at T1 and T2 11 years apart (Supporting Information Figure S1 ); the coefficient remained positive and statistically significant after adjusting for covariates ( = 0.70, P < .0001). The majority of participants (61%) had stable decile rankings in LTLs over the 11-year follow-up; the remaining 20% and 19% had upward and downward decile ranking shifts, respectively (Supporting Information Figure S2 ).
The mean ages and age-standardized characteristics of the study participants at T1 are shown in Table 1 by DS of LTLs between T1 and T2. Compared to women whose rankings in LTLs were stable between T2 and T1, those with upward DS in LTL rank had a slightly higher prevalence of antidepressant use at baseline. Women with downward DS in LTL rank had higher prevalence of severe depressive symptoms at baseline (defined by MHI-5 ≤ 52).
Although age-at-blood draw and paternal age at participant's birth, respectively, had statistically significant inverse (F 1,1249 = 10.38, P = .001) and positive (F 1,1249 = 11.50, P < .0001) correlations with LTLs at baseline, they were not significantly associated with 11-year AC in LTLs (all P > .05). None of the other covariates had statistically significant associations with DS over 11 years in the age-adjusted models (all P > .05). The only factor that showed a significant association with DS of LTLs was baseline LTLs (F 1,1249 = 300.10, P < .0001). A significant inverse relation also existed between baseline LTL and 11-year LTL change in absolute values ( = -0.29, P < .0001 after adjusting for covariates). Specifically, participants with longer baseline LTLs were more likely to be observed to have subsequent TL shortening, whereas apparent telomere lengthening was more likely to be observed among those with shorter baseline LTLs (i.e., "regression-to-the-mean" phenomenon) (Supporting Information Figure S3 ).
Overall, there was no statistically significant association between baseline depression status and subsequent accelerated telomere shortening over 11 years. Examining point estimates, however, participants with depression at baseline had respective nonsignificant 1.6-fold (F 1,1249 = 1.72, P = .19) ( Table 2 ) and 1.8-fold (F 1,1249 = 2.51, P = .11) (Table 3) decreases in AC and SPC over 11 years, relative to those without depression, and 1.5-fold (95% CI, 0.87-2.54) of relative likelihood of having a downward shift in DS over 11 years (Table 4) .
When depression was alternatively defined by both antidepressant use and the presence of severe depressive symptoms, those with depression had greater declines telomere length on both the AC (1.8-fold) and SPC (2.6-fold) metrics; however, the number of depression cases was reduced substantially (N = 12), as expected, by this Boolean AND definition.
We did not observe significant associations between baseline phobic anxiety and higher LTL attrition rate between two time points.
The age-adjusted and multivariable-adjusted analyses yielded similar results. In the multivariable-adjusted models, compared to participants with minimal phobic anxiety symptoms (CCI ≤ 1), those with CCI scores of 2, 3, 4-5, 6+ had similar levels of LTL shortening for both the AC (F 4,1249 = 0.19, P = .94; Table 2) or SPC (F 4,1249 = 0.21, P = .93; Table 3) outcome, and they did not have a significantly greater odds of having downward DS in telomere lengths (Table 4) .
DISCUSSION
In this prospective study involving 1,250 mid-life and older U.S. women, we did not observe statistically significant associations of depression or anxiety with change in telomere lengths over 11 years. When considering all three metrics of telomere length change, point estimates were in the direction of more accelerated telomere shortening among persons with versus without depression at baseline; however, these associations were not statistically significant. The largest determinant of observed changes in telomere length was the baseline telomere length, and regression-to-the-mean was present.
Regarding the association between depression and telomere length in the literature, individual studies have shown mixed results; however, an overall significant association between depressive disorders and shorter telomere length has been observed in meta-analyses (Darrow et al., 2016; Lin et al., 2016; Schutte & Malouff, 2015) . Nevertheless, most studies were conducted cross-sectionally, and there have been few prospective studies that could address temporality. Shalev et al. TA B L E 1 Age-Standardized characteristics of study population at initial blood draw, by decile shift in ranking of relative leukocyte telomere lengths (N = 1,250) a Eleven-year absolute change in relative leukocyte telomere length was defined by exponentiated T∕S ratio at T2 − exponentiated T∕S ratio at T1. b Model adjusted for age at first blood draw (continuous) and baseline LTL (continuous). c Model adjusted for age at first blood draw (continuous), baseline LTL (continuous), paternal age at birth (continuous), pack-years of smoking (never, >0-20, >20-40, >40, missing) , body mass index (continuous), and physical activity (continuous). d Depression was defined by antidepressant use at initial blood draw or MHI-5 ≤ 52 on the 1992 questionnaire; 66 participants who did not answer question on antidepressant use at initial blood draw were not included. e Phobic anxiety score was measured by Crown-Crisp Phobic Index on the 1988 questionnaire. a 11-year change in relative leukocyte telomere length was calculated by symmetrized percent change, defined by exponentiated T/S ratio at T2 − exponentiated T/S ratio at T1)/(exponentiated T/S ratio at T2 + exponentiated T/S ratio at T1 × 100 b Model adjusted for age at first blood draw (continuous). c Model adjusted for age at first blood draw (continuous), paternal age at birth (continuous), pack-years of smoking (never, >0-20, >20-40, >40, missing) , body mass index (continuous), and physical activity (continuous). d Depression was defined by antidepressant use at initial blood draw or MHI-5 ≤ 52 on the 1992 questionnaire. e Phobic anxiety score was measured by Crown-Crisp Phobic Index on the 1988 questionnaire.
TA B L E 3 Least-Squares mean (95% CI
) symmetrized percent change in relative leukocyte telomere length, by categories of baseline mental health outcomes
TA B L E 4
Odds ratio (95% CI) of 11-Year decile shift in relative leukocyte telomere length by categories of baseline mental health outcomes a a Decile shift was defined as the difference of decile ranking in relative telomere lengths estimated by exponentiated T/S ratio between second and initial blood draw: referent group being stable in decile shift over 10 years of LTL (within ±1 decile shift); shifting upward was defined as >1 decile increase; shifting downward was defined as >1 decile decrease. Multinomial logistic regression was used to examine the associations. b Model adjusted for age at first blood draw (continuous) and baseline LTL (continuous). c Model adjusted for age at first blood draw (continuous), baseline LTL (continuous), paternal age at birth (continuous), pack-years of smoking (never, >0-20, >20-40, >40, missing) , body mass index (continuous), and physical activity (continuous). d Depression was defined by antidepressant use at initial blood draw or MHI-5 ≤ 52 on the 1992 questionnaire. 66 participants who did not answer question on antidepressant use at initial blood draw were not included. e Phobic anxiety score was measured by Crown-Crisp Phobic Index on the 1988 questionnaire.
11-Year Decile Shift in LTL
association between depression and shorter telomeres at 2-year follow-up among 974 mid-life men and women. Interestingly, in a study (Hoen et al., 2011) of 608 predominantly older male patients with coronary heart disease, depression appeared associated with a lower likelihood of 5-year subsequent telomere shortening; however, this association was attenuated and no longer statistically significant after adjusting for anxiety and baseline telomere length. Although these investigations differed by study design, sample size, follow-up durations, participants' ages, sex, and health characteristics (e.g., healthy population vs. patients with heart disease), the results are generally consistent with our current finding of a lack of statistically significant associations between depression and LTL shortening over time. Nevertheless, a pattern suggestive of greater decreases in telomere lengths with depression at baseline was consistently noted on all three LTL change metrics. This finding may warrant further investigation, especially in studies with somewhat larger sample sizes that can overcome intrinsic limitations of statistical power due to random measurement error in the qPCR telomere measure.
Anxiety has also been studied with regard to telomere length, although its relation to telomere length has been examined more frequently in conjunction with depression (Hoen et al., 2013; Shalev et al., 2014; Verhoeven et al., 2016) . In work by Hoen et al., (2013) , the presence of anxiety disorders was significantly associated with shorter telomeres at 2-year follow-up among mid-life men and women, but the association was no longer significant after adjustment for baseline telomere length. In the paper by Shalev et al., (2014) , participants who experienced GAD between ages 26 and 38 years showed significantly accelerated LTL erosion during this same 12-year time frame compared to those without GAD; however, as was the case for MDD and LTL erosion, this association was only observed among men. Although our prior finding in the NHS cohort identified a significant cross-sectional association of phobic anxiety with shorter telomere lengths, we did not observe a prospective association between phobic anxiety and telomere length shortening over 11 years in the current study. It is notable, however, that our data cannot inform the issue of whether relations of anxiety to accelerated telomere shortening may exist among younger people.
The strengths of the study include a well-characterized sample of generally healthy, community-dwelling participants; prospective study design; and high-quality information on relevant health, lifestyle, and demographic factors. Potential limitations should also be noted. First, the study examined the presence of depression and phobic anxiety with respect to changes in telomere length between ages 57 and 68
years. This may not be the most sensitive time window for addressing these associations, as the rate of telomere attrition is most rapid in earlier life periods (Weng, 2008) . Second, compared to prior studies which measured LTLs using the Southern blot method (Aviv et al., 2009 ), more participants showed gain in telomere length in our study, in which LTLs were measured by qPCR; this suggests importance of technical differences in the telomere assay methods. There are two key sources of random measurement error in the qPCR-based T/S ratio calculation at each time point (i.e., from both the telomere and single control gene assays). As even greater random measurement error is involved in computing changes in T/S ratios between two time points, associations may be biased toward the null (Aviv et al., 2011) . Third, despite a comparatively large sample size, adequate power was an issue for some analyses: for example, in this generally healthy sample of 1,250 women, there were fewer than 100 participants who regularly used antidepressants or had severe depressive symptoms at baseline. Furthermore, the adverse impact of random error on statistical power may be even more pronounced in this study, where the available sample size was lower than those in prior analyses of anxiety and telomere lengths in this cohort (Okereke et al., 2012; Ramin et al., 2015) . Fourth, misclassification of depression was possible; as such misclassification is more likely to be nondifferential, it could bias results toward the null. Fifth, residual confounding is possible, as in all observational designs. However, we performed multivariable-adjusted analyses that controlled for carefully measured potential confounders, and results were similar when compared to age-adjusted estimates; therefore, residual confounding may be less of a concern. Lastly, the study was conducted among mid-life and older women who were predominantly non-Latino white (prevalence of minority race/ethnicity is 5% in the NHS). Homogeneity of study participants may strengthen internal validity, but the findings may not be generalizable to males or to other racial, ethnic, and/or age groups (Diez Phillips et al., 2013; Roux et al., 2009; Shalev et al., 2014) .
In summary, we did not observe that either depression or anxiety was significantly associated with subsequent change in telomere lengths over 11 years among middle-aged and older women. However, when considering all three metrics of telomere length change, the point estimates suggested a pattern of more accelerated telomere shortening over follow-up among persons with versus without depression, and this finding may warrant further inquiry. Future prospective studies would be enhanced by addressing broader windows of the lifespan, including larger sample sizes in order to increase power, and using psychological measures that maximize contrasts in characterizing persons with depression or anxiety versus those without these conditions.
